RP
WST icon

Riverbridge Partners’s West Pharmaceutical WST Stock Holding History

Riverbridge Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.5M Sell
232,514
-28,928
-11% -$8.84M 2.33% 10
2026
Q1 		$65.5M Sell
261,442
-57,171
-18% -$14.2M 1.6% 18
2025
Q4 		$87.7M Sell
318,613
-43,927
-12% -$12M 1.64% 19
2025
Q3 		$95.1M Sell
362,540
-20,980
-5% -$5.1M 1.6% 19
2025
Q2 		$83.9M Sell
383,520
-24,886
-6% -$5.32M 1.35% 27
2025
Q1 		$91.4M Sell
408,406
-26,887
-6% -$7.41M 1.47% 21
2024
Q4 		$143M Sell
435,293
-21,456
-5% -$6.75M 1.95% 14
2024
Q3 		$137M Sell
456,749
-30,187
-6% -$9.24M 1.83% 16
2024
Q2 		$160M Sell
486,936
-14,955
-3% -$5.29M 2.18% 9
2024
Q1 		$199M Sell
501,891
-14,132
-3% -$5.23M 2.42% 10
2023
Q4 		$182M Sell
516,023
-7,996
-2% -$2.83M 2.27% 11
2023
Q3 		$197M Sell
524,019
-39,484
-7% -$15.3M 2.68% 7
2023
Q2 		$216M Buy
563,503
+22,613
+4% +$8.08M 2.72% 6
2023
Q1 		$187M Buy
540,890
+33,504
+7% +$9.79M 2.63% 8
2022
Q4 		$119M Sell
507,386
-22,125
-4% -$5.24M 1.79% 18
2022
Q3 		$130M Buy
529,511
+65,985
+14% +$20.1M 1.93% 15
2022
Q2 		$140M Sell
463,526
-92,868
-17% -$30.2M 2.24% 8
2022
Q1 		$229M Sell
556,394
-61,815
-10% -$24.2M 2.58% 7
2021
Q4 		$290M Buy
618,209
+24
+0% +$10.3K 2.87% 3
2021
Q3 		$262M Buy
618,185
+1,433
+0.2% +$604K 2.63% 4
2021
Q2 		$221M Buy
616,752
+24,628
+4% +$8.14M 2.25% 7
2021
Q1 		$167M Buy
592,124
+27,808
+5% +$7.96M 1.9% 12
2020
Q4 		$160M Sell
564,316
-23,904
-4% -$6.71M 1.77% 19
2020
Q3 		$162M Sell
588,220
-17,461
-3% -$4.62M 2.26% 10
2020
Q2 		$138M Buy
605,681
+21,679
+4% +$4.26M 2.16% 11
2020
Q1 		$88.9M Sell
584,002
-4,653
-0.8% -$716K 1.86% 17
2019
Q4 		$88.5M Sell
588,655
-3,494
-0.6% -$509K 1.59% 22
2019
Q3 		$84M Buy
592,149
+10,153
+2% +$1.4M 1.59% 23
2019
Q2 		$72.8M Sell
581,996
-25,441
-4% -$3M 1.38% 28
2019
Q1 		$66.9M Sell
607,437
-12,026
-2% -$1.25M 1.3% 27
2018
Q4 		$60.7M Sell
619,463
-28,517
-4% -$3.09M 1.27% 27
2018
Q3 		$80M Buy
647,980
+177,637
+38% +$19.9M 1.34% 27
2018
Q2 		$46.7M Sell
470,343
-18,863
-4% -$1.74M 0.84% 48
2018
Q1 		$43.2M Sell
489,206
-2,092
-0.4% -$196K 0.79% 49
2017
Q4 		$48.5M Sell
491,298
-30,506
-6% -$2.99M 0.94% 39
2017
Q3 		$50.2M Buy
521,804
+10,381
+2% +$939K 0.99% 40
2017
Q2 		$48.3M Buy
+511,423
New +$47M 0.92% 45

Other funds holding WST

SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
BZWA
Blue Zone Wealth Advisors Los Angeles, California $573M AUM 22.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Riverbridge Partners's WST Position: Q2 2026 in Review

Riverbridge Partners reduced its West Pharmaceutical (WST) stake by 11% in Q2 2026, selling an estimated $8.84M and leaving 232,514 shares worth $83.5M. The position accounts for 2.33% of the portfolio, ranked #10.

Riverbridge Partners first reported a position in WST in Q2 2017 and has held it in 37 quarters since. The position peaked at $290M in Q4 2021. 97 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Riverbridge Partners held 232,514 shares of West Pharmaceutical worth $83.5M as of Q2 2026.
  • Riverbridge Partners sold 28,928 West Pharmaceutical shares in Q2 2026, an estimated $8.84M.
  • West Pharmaceutical made up 2.33% of Riverbridge Partners's portfolio in Q2 2026, its #10 holding.
  • Riverbridge Partners first reported a position in West Pharmaceutical in Q2 2017 and has held it in 37 quarters since.
  • Riverbridge Partners's West Pharmaceutical position peaked at $290M in Q4 2021.
  • 97 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Riverbridge Partners's 13F filing for Q2 2026, filed 13 Jul 2026.